Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens

Therapeutic Drug Monitoring

Volumn 23, Issue 4, 2001, Pages 332-340

  Pellegrin, Isabelle ^a,c   Breilh, Dominique ^a   Birac, Vaĺrie ^a   Deneyrolles, Muriel ^a   Mercié, Patrick ^a   Trylesinski, Aldo ^b   Neau, Didier ^a   Saux, Marie Claude ^a   Fleury, Herv́ J A ^a   Pellegrin, Jean Luc ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Roche Affiliate   (France)

^c HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; RNA, VIRAL; SAQUINAVIR; VIRAL LOAD;

EID: 0034896883     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200108000-00003     Document Type: Article

References (30)

1. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS Society-USA Panel
2. Antiretroviral drug resistance testing in adults with HIV infection. Implication for clinical management
3. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations
4. + T-cell counts in HIV-infected patients
5. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959
6. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients
7. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
8. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
9. Resistance to human immunodeficiency virus type 1 protease inhibitors
10. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
11. Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human serum by high-performance liquid chromatography
12. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
13. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
14. Virological response to protease inhibitor therapy in an HIV clinic cohort
15. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
16. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitors therapy had failed
17. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program
18. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
19. Impact of drug resistance mutations on virologic response to salvage therapy
20. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcription gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy
21. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
22. Impact of zidovudine-lamivudine resistance mutations on phenotypic susceptibility of HIV-1 isolates to abacavir and stavudine using a HeLa LacZ CD4 CCR5 cell indicator assay
23. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
24. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
25. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
26. Relevance of protease inhibitor (PI) plasma levels in patients treated with genotypic adapted therapy pharmacological data from the VIRADAPT study
27. Population pharmacokinetics of stavudine in patients with AIDS or advanced AIDS-related complex
28. Zalcitabine population pharmacokinetics: Application of radioimmunoassay
29. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients
30. The potential role of resistance testing and therapeutic drug monitoring in the optimization of antiretroviral drug therapy